These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4355 related articles for article (PubMed ID: 10334980)
1. Bacterial biofilms: a common cause of persistent infections. Costerton JW; Stewart PS; Greenberg EP Science; 1999 May; 284(5418):1318-22. PubMed ID: 10334980 [TBL] [Abstract][Full Text] [Related]
2. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303 [TBL] [Abstract][Full Text] [Related]
3. Pseudomonas aeruginosa biofilm infections: from molecular biofilm biology to new treatment possibilities. Tolker-Nielsen T APMIS Suppl; 2014 Dec; (138):1-51. PubMed ID: 25399808 [TBL] [Abstract][Full Text] [Related]
5. The role of bacterial biofilms in chronic infections. Bjarnsholt T APMIS Suppl; 2013 May; (136):1-51. PubMed ID: 23635385 [TBL] [Abstract][Full Text] [Related]
6. Gentamicin resistance in biofilm producing Pseudomonas aeruginosa causing catheter associated urinary tract infections. Suman E; Varghese S; Jose J Indian J Med Sci; 2005 May; 59(5):214-6. PubMed ID: 15985732 [No Abstract] [Full Text] [Related]
7. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Murray TS; Egan M; Kazmierczak BI Curr Opin Pediatr; 2007 Feb; 19(1):83-8. PubMed ID: 17224667 [TBL] [Abstract][Full Text] [Related]
8. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Høiby N; Krogh Johansen H; Moser C; Song Z; Ciofu O; Kharazmi A Microbes Infect; 2001 Jan; 3(1):23-35. PubMed ID: 11226851 [TBL] [Abstract][Full Text] [Related]
9. Pseudomonas aeruginosa Biofilms: Host Response and Clinical Implications in Lung Infections. Maurice NM; Bedi B; Sadikot RT Am J Respir Cell Mol Biol; 2018 Apr; 58(4):428-439. PubMed ID: 29372812 [TBL] [Abstract][Full Text] [Related]
10. Lee K; Yoon SS J Microbiol Biotechnol; 2017 Jun; 27(6):1053-1064. PubMed ID: 28301918 [TBL] [Abstract][Full Text] [Related]
12. The Consequences of Being in an Infectious Biofilm: Microenvironmental Conditions Governing Antibiotic Tolerance. Sønderholm M; Bjarnsholt T; Alhede M; Kolpen M; Jensen PØ; Kühl M; Kragh KN Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29231866 [TBL] [Abstract][Full Text] [Related]
13. The clinical impact of bacterial biofilms. Høiby N; Ciofu O; Johansen HK; Song ZJ; Moser C; Jensen PØ; Molin S; Givskov M; Tolker-Nielsen T; Bjarnsholt T Int J Oral Sci; 2011 Apr; 3(2):55-65. PubMed ID: 21485309 [TBL] [Abstract][Full Text] [Related]
14. Airway biofilms: implications for pathogenesis and therapy of respiratory tract infections. Kobayashi H Treat Respir Med; 2005; 4(4):241-53. PubMed ID: 16086598 [TBL] [Abstract][Full Text] [Related]
15. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009528. PubMed ID: 28981972 [TBL] [Abstract][Full Text] [Related]
16. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Smith S; Waters V; Jahnke N; Ratjen F Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436 [TBL] [Abstract][Full Text] [Related]
17. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647 [TBL] [Abstract][Full Text] [Related]
18. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2015 Mar; (3):CD009528. PubMed ID: 25741986 [TBL] [Abstract][Full Text] [Related]